Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3WA2V
|
|||
| Drug Name |
ABC008
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Inclusion body myositis [ICD-11: 4A41.2; ICD-10: G72.8] | Phase 2/3 | [1] | |
| Company |
Abcuro
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Killer cell lectin-like receptor subfamily G member 1 (KLRG1) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05721573) A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Abcuro | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.